Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human PLAU Anticorps:
anti-Mouse (Murine) PLAU Anticorps:
anti-Rat (Rattus) PLAU Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal PLAU Primary Antibody pour IHC (fro), ELISA - ABIN2192594
Nielsen, Grøndahl-Hansen, Andreasen, Skriver, Zeuthen, Danø: Enzyme-linked immunosorbent assay for human urokinase-type plasminogen activator and its proenzyme using a combination of monoclonal and polyclonal antibodies. dans Journal of immunoassay 1986
Show all 4 Pubmed References
Human Monoclonal PLAU Primary Antibody pour IHC (fro), ELISA - ABIN2192596
Kaltoft, Nielsen, Zeuthen, Danø: Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme. dans Proceedings of the National Academy of Sciences of the United States of America 1982
Show all 4 Pubmed References
Mouse (Murine) Monoclonal PLAU Primary Antibody pour ELISA (Capture), ELISA (Detection) - ABIN491262
Botkjaer, Deryugina, Dupont, Gårdsvoll, Bekes, Thuesen, Chen, Chen, Ploug, Quigley, Andreasen: Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism. dans Molecular cancer research : MCR 2012
Show all 3 Pubmed References
Human Monoclonal PLAU Primary Antibody pour IHC (fro), ELISA - ABIN2192590
Grøndahl-Hansen, Christensen, Rosenquist, Brünner, Mouridsen, Danø, Blichert-Toft: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. dans Cancer research 1993
Show all 3 Pubmed References
Human Polyclonal PLAU Primary Antibody pour IHC (p), ELISA - ABIN544968
Türkmen, Schmitt, Schmalfeldt, Trommler, Hell, Creutzburg, Graeff, Magdolen: Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer. dans Electrophoresis 1997
Show all 3 Pubmed References
Human Polyclonal PLAU Primary Antibody pour WB - ABIN6715032
Luo, Sun, Gao, Zhao, Zhong, Wang, Sun: Effects of ulinastatin and docetaxel on breast cancer invasion and expression of uPA, uPAR and ERK. dans Journal of experimental & clinical cancer research : CR 2012
Show all 2 Pubmed References
Human Polyclonal PLAU Primary Antibody pour EIA, IHC (fro) - ABIN191518
Coy, Jiménez-Movilla, García-Vázquez, Mondéjar, Grullón, Romar: Oocytes use the plasminogen-plasmin system to remove supernumerary spermatozoa. dans Human reproduction (Oxford, England) 2012
Show all 2 Pubmed References
Human Monoclonal PLAU Primary Antibody pour ELISA (Capture), ELISA (Detection) - ABIN491259
Florova, Azghani, Karandashova, Schaefer, Koenig, Stewart-Evans, Declerck, Idell, Komissarov: Targeting of plasminogen activator inhibitor 1 improves fibrinolytic therapy for tetracycline-induced pleural injury in rabbits. dans American journal of respiratory cell and molecular biology 2015
Show all 2 Pubmed References
Human Polyclonal PLAU Primary Antibody pour ELISA, IHC - ABIN6264278
Liu, Zheng, Zhang, Wang, Yang, Bai, Dai: Fucoxanthin Activates Apoptosis via Inhibition of PI3K/Akt/mTOR Pathway and Suppresses Invasion and Migration by Restriction of p38-MMP-2/9 Pathway in Human Glioblastoma Cells. dans Neurochemical research 2017
Human Polyclonal PLAU Primary Antibody pour ELISA, WB - ABIN5692920
Wu, Li, Liu, Ning, Li: Effects of Guiyuanfang and autologous transplantation of bone marrow stem cells on rats with liver fibrosis. dans World journal of gastroenterology 2005
TEM8 is a novel receptor for uPA
Study indicates that uPA and PAI-1 tumor tissue levels and 4G/5G variants of PAI-1 gene might be of prognostic significance in early node-negative luminal HER2-negative breast cancer patients treated with adjuvant endocrine therapy.
Transient knockdown of urokinase/plasminogen activator urokinase receptor (uPAR) in basal-like breast cancer cells grown on vitronectin reduces FRA-1 phosphorylation and stabilization; and uPAR and FRA-1 are required for vitronectin-induced cell invasion
The combination of decoy receptor 3, soluble urokinase type plasminogen activator receptor, and procalcitonin improved the sensitivity and specificity of diagnosis of sepsis, suggesting that use of the combination of three indexes enhanced the efficiency of sepsis diagnosis.
The personalization of the patients' treatment using uPA/PAI-1 tumor levels allows the reversion of the well-known poor prognostic impact of high uPA/PAI-1 levels and strongly supports the use of this biomarker in clinical practice.
High Expressions of PLAU is associated with lung adenocarcinoma.
Adjuvant chemotherapy was 9% less likely to be recommended by a multidisciplinary board when using the current criteria compared with using a combination of the St. Gallen criteria and Ki67 and uPA/PAI-1 status (P = 0.03). Taken together, our data show discordance among markers in identifying the risk of recurrence, even though each marker may prove to be independently valid.
Increased expression of uPA in epidermal cells in psoriasis and in tumor cells in basal cell carcinomas suggests an important role of the uPA system for aggressively proliferating and invading cells of epidermal origin.
study provides strong support in the role of L. reuteri in suppression of GC cell invasion by downregulation of pathways which is involved in extracellular matrix degradation such as uPA and uPAR
uPA protection is independent of its catalytic activity, as the amino terminal fragment of uPA showed similar protection. A key enzyme for repairing oxidative DNA damage is the p53 target hOGG1. We found a significant increase of hOGG1 after pretreatment of HACM with uPA. Knockdown of hOGG1 completely abrogated the protective effect of uPA
We show that the tumor-suppressive actions of MEPs are mediated by PAI-1, uPA and its receptor, uPAR, and are sustained even in the presence of the CAFs, which themselves enhance DCIS tumorigenesis via IL-6 signaling.
Gelsolin enhances the invasive capacity of colon cancer cells via elevating intracellular superoxide (O2.-) levels by interacting with Cu/ZnSOD, and gelsolin gene expression positively correlates with urokinase plasminogen activator (uPA), an important matrix-degrading protease invovled in cancer invasion.
the optimal discrimination cut-off for each cytokine: sVEGFR-1 (2124.5pg/mL), IL-6 (40.2pg/mL), VEGF-A (1060.1pg/mL), Angiopoeintin-2 (913.7pg/mL), uPA (248.1pg/mL), sHER-2/neu (5010pg/mL) and PLGF (93.4pg/mL). For the very first time, a novel cytokine profile associated with cancer metastasis to the paratracheal lymph nodes were reported.
Study provides evidence that the stimulation of u-PA/u-PAR system contributes to the activated phenotype and function of cancer-associated fibroblasts during multiple myeloma.
OB-Rb, RhoA/ROCK, PI3K/AKT, JAK/STAT pathways and NF-kB activation are involved in leptin-induced upA expression.
Results provide evidence that uPA and IGF1R directly interact with uPAR enhancing malignant potential of triple-negative breast cancer.
suggest that the low endogenous levels of uPA in blood are actively regulated, and that the regulatory mechanisms are disrupted in QPD in a megakaryocyte-specific manner
an intricate link between caveolin-1 and Src kinase-mediated cell signaling and alveolar epithelial cell apoptosis due to loss of SP-C expression through p53 and uPA system-mediated cross-talk, is reported.
results show that the uPA/uPAR/LRP1 system is a potential target for the development of therapeutic strategies to promote axonal recovery following a CNS injury
The present research concluded that aspirin suppressed prostate cancer cell invasion by reducing MMP-9 activity and uPA expression through decreasing of IKK-beta-mediated NF-kappaB activation, indicating that the ability of aspirin to inhibit cell invasion might be useful in the chemoprevention of metastatic prostate cancer.
The findings of this indicated that Plau/Plaur-deficiency leads to a more social phenotype toward other mice with diminished interest in the surrounding environment, and increased seizure susceptibility
In summary, the data show that urokinase-type plasminogen activator/ the urokinase-type plasminogen activator receptor binding promotes synaptic repair in the ischemic brain via ezrin-mediated reorganization of the actin cytoskeleton in the postsynaptic terminal.
downregulation of uPA could decrease the fertility of male mice, which may be caused by a reduction in sperm motility.
data presented here reveal important information about dynamics in uPA by demonstrating how various ligands can modulate uPA activity by mediating long-range conformational changes
Lymphangioleiomyomatosis is fatal lung disease associated with germline/somatic inactivating mutations in TSC2 genes. Data suggest lung lymphangioleiomyomatosis lesions and renal angiomyolipomas overexpress uPA; Tsc2-/- (or Tsc1-/-) embryonic fibroblasts from knockout mice express higher uPA levels than wild-type cells. (uPA = urokinase-type plasminogen activator; Tsc = tuberous sclerosis complex protein)
The findings suggest that the absence of uPA correlates with increased levels of Runx transcriptional regulators in a way that promotes inflammation-associated carcinogenesis.
These studies identify uPA-dependent de-repression of vegfr1 and vegfr2 gene transcription through binding to HHEX/PRH as a novel mechanism by which uPA mediates the pro-angiogenic effects of VEGF and identifies a potential new target for control of pathologic angiogenesis.
Significance of the urokinase-type plasminogen activator and its receptor in the progression of focal segmental glomerulosclerosis in clinical and mouse models.
GM-CSF and uPA are required for Porphyromonas gingivalis-induced alveolar bone loss in a mouse periodontitis model.
Plau deficiency does not worsen controlled cortical impact-induced brain pathology or epileptogenesis caused by TBI.
we have firstly shown a fundamental mechanism of urokinase system(uPa and uPAR)-dependent regulation of the trajectory of growth and branching of blood vessels in early embryogenesis and in adults during the repair/regeneration of tissues.
Pharmacological inhibition of either uPA or selected MMPs decreased atherosclerosis in transgenic uPA mice.
Study shows that the competitive expression or activity of tPA and/or PAI-1, rather than an altered uPA expression, determines the plasmin-mediated Abeta proteolysis in brains affected by Alzheimer's disease
Porphyromonas gingivalis-derived RgpA-Kgp complex activates the macrophage uPA.
beta-elemene downregulates expression of uPA, uPAR, MMP-2, and MMP-9 in a murine intraocular melanoma model
Data indicate that closed head trauma sequentially releases tissue-type plasminogen activator (tPA) followed by delayed synthesis and release of urokinase plasminogen activator (uPA) from injured brain.
transgenic alphaMUPA mice, with genetically extended life span, showed a much slower age-related decline in the rate of wound healing than their wild-type counterparts
Binding of urokinase to urokinase plasminogen activator receptor promotes dendritic spine recovery and functional outcome after ischemic stroke.
Protein kinase C-delta mediates sepsis-induced activation of complement 5a and urokinase-type plasminogen activator signaling in macrophages
Urokinase-type plasmiogen activator protein expression is increased in spinal cord tissues from animals with cervical spondylotic myelopathy.
uPA-mediated arterial constriction is a vasomotor process that is mediated by uPA catalytic activity, not by the NH(2)-terminal domains.
Urokinase plasminogen activator expression in the oviducts.
Data suggest endogenous uPA activity plays important role in oocyte maturation; these studies were conducted using in vitro oocyte maturation techniques.
Data show that urokinase-type plasminogen activator (uPA) is only expressed in the cumulus cells of immature and in vitro matured cumulus-oocyte complexes (COCs), while uPA receptor (uPAR) and plasminogen activator inhibitor-1 (PAI-1) are expressed in both the cumulus cells and the immature and in vitro matured oocytes.
uPA/uPAR binding is involved in signaling pathways that activate transcription factors that regulate the synthesis of molecules concerned with the arrangement of a particular oviductal microenvironment.
These data indicated that E. coli LPS led to an increase in u-PA activity and RNA expression of u-PA and u-PAR in BME-UV1 cells, thus strengthening the role of the PA system during pathological processes.
The plasminogen/plasminogen activator/plasmin system is activated during gamete interaction and regulates the sperm entry into the oocyte.
stage-dependent regulation of granulosa cell PA and SerpinE2 production, consistent with a role in extracellular matrix remodeling during follicle growth.
This gene encodes a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. A specific polymorphism in this gene may be associated with late-onset Alzheimer's disease and also with decreased affinity for fibrin-binding. This protein converts plasminogen to plasmin by specific cleavage of an Arg-Val bond in plasminogen. Plasmin in turn cleaves this protein at a Lys-Ile bond to form a two-chain derivative in which a single disulfide bond connects the amino-terminal A-chain to the catalytically active, carboxy-terminal B-chain. This two-chain derivative is also called HMW-uPA (high molecular weight uPA). HMW-uPA can be further processed into LMW-uPA (low molecular weight uPA) by cleavage of chain A into a short chain A (A1) and an amino-terminal fragment. LMW-uPA is proteolytically active but does not bind to the uPA receptor. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
urokinase-type plasminogen activator
, U-plasminogen activator
, plasminogen activator, urokinase
, plasminogen activator, urinary
, Urinary plasminogen activator, urokinase
, urokinase plasminogen activator preproprotein